Changing the future of Oncology.
Bispecific and Engineered Antibodies
Sutro’s cell-free expression technology provides a rapid and powerful platform for the discovery and development of antibodies that bind simultaneously to two separate antigens (bispecific antibodies).
Bispecific antibodies can be designed to achieve different purposes:
While many different bispecific antibody formats have been exemplified using cell-based expression systems, and some have been successful enough to show promise as new therapeutics, the precise geometry and spatial orientation of binding domains, linkers and functional domains can be a challenge to optimize. Additionally, the use of cell-based systems has revealed immense difficulties in expressing bispecific antibodies, particularly at larger scale, often resulting in poorly folded and aggregated material. Consequently, using traditional cell-based technologies prevents researchers from discovering and developing bispecific candidates with optimal therapeutic indices and can result in products with unpredictable pharmacokinetic properties, stability and efficacy.
Sutro’s technology has the ability to perform rapid expression and characterization of many variants early in discovery to define structure-activity relationships and thereby optimize:
Sutro can rapidly screen candidates to identify molecules with the best overall combination of these properties resulting in optimized product candidates.